File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis

TitleEffect of Sanguisorba officinalis L on breast cancer growth and angiogenesis
Authors
Issue Date2012
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
Citation
Expert Opinion On Therapeutic Targets, 2012, v. 16 SUPPL. 1, p. S79-S89 How to Cite?
AbstractObjective: Sanguisorba officinalis L. (SA) has shown anti-inflammation, hematopoiesis and immunity enhancing properties. No detailed studies have been reported on its anti-cancer effects. This study therefore was undertaken to analyze its effects on human breast cancer utilizing in vitro and in vivo methodologies. Methods: Human breast cancer cell lines MCF-7 and MDA-MB-231 were utilized for evaluating SA influences on tumor progression and angiogenesis processes like proliferation, the cell cycle, apoptosis, tube formation and migration abilities. Both cancer xenografts were also used to determine the herb efficacy in vivo. Bioactivity-guided fractionation was carried out to determine the bioactive compounds in SA. Results: SA inhibited proliferation, induced S phase arrest and triggered mitochondrial pathway apoptosis in both cancer cells. Angiogenesis experiments revealed that SA inhibited VEGF expression in both cancer cell lines. Meanwhile, the proliferation, tube formation and migration abilities of endothelial cells were also inhibited. In vivo experiments demonstrated that SA reduced tumor size and neoangiogenesis in both cancer xenografts. Gallic acid and ellagic acid were finally identified as bioactive compounds in SA. Conclusions: SA might be of value as a breast cancer preventive and therapeutic agent by inducing apoptosis and inhibiting angiogenesis. Further research is needed to evaluate its metabolism and synergistic effects with chemotherapeutic drugs. © 2012 Informa UK, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/179465
ISSN
2015 Impact Factor: 4.798
2015 SCImago Journal Rankings: 2.025
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWang, Zen_US
dc.contributor.authorLoo, WTYen_US
dc.contributor.authorWang, Nen_US
dc.contributor.authorChow, LWCen_US
dc.contributor.authorWang, Den_US
dc.contributor.authorHan, Fen_US
dc.contributor.authorZheng, Xen_US
dc.contributor.authorChen, JPen_US
dc.date.accessioned2012-12-19T09:56:50Z-
dc.date.available2012-12-19T09:56:50Z-
dc.date.issued2012en_US
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2012, v. 16 SUPPL. 1, p. S79-S89en_US
dc.identifier.issn1472-8222en_US
dc.identifier.urihttp://hdl.handle.net/10722/179465-
dc.description.abstractObjective: Sanguisorba officinalis L. (SA) has shown anti-inflammation, hematopoiesis and immunity enhancing properties. No detailed studies have been reported on its anti-cancer effects. This study therefore was undertaken to analyze its effects on human breast cancer utilizing in vitro and in vivo methodologies. Methods: Human breast cancer cell lines MCF-7 and MDA-MB-231 were utilized for evaluating SA influences on tumor progression and angiogenesis processes like proliferation, the cell cycle, apoptosis, tube formation and migration abilities. Both cancer xenografts were also used to determine the herb efficacy in vivo. Bioactivity-guided fractionation was carried out to determine the bioactive compounds in SA. Results: SA inhibited proliferation, induced S phase arrest and triggered mitochondrial pathway apoptosis in both cancer cells. Angiogenesis experiments revealed that SA inhibited VEGF expression in both cancer cell lines. Meanwhile, the proliferation, tube formation and migration abilities of endothelial cells were also inhibited. In vivo experiments demonstrated that SA reduced tumor size and neoangiogenesis in both cancer xenografts. Gallic acid and ellagic acid were finally identified as bioactive compounds in SA. Conclusions: SA might be of value as a breast cancer preventive and therapeutic agent by inducing apoptosis and inhibiting angiogenesis. Further research is needed to evaluate its metabolism and synergistic effects with chemotherapeutic drugs. © 2012 Informa UK, Ltd.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/etten_US
dc.relation.ispartofExpert Opinion on Therapeutic Targetsen_US
dc.subject.meshAnimalsen_US
dc.subject.meshApoptosis - Drug Effectsen_US
dc.subject.meshBreast Neoplasms - Blood Supply - Drug Therapy - Pathologyen_US
dc.subject.meshCell Cycle Checkpoints - Drug Effectsen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCell Proliferation - Drug Effectsen_US
dc.subject.meshEllagic Acid - Pharmacologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshGallic Acid - Pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMiceen_US
dc.subject.meshNeovascularization, Pathologic - Drug Therapyen_US
dc.subject.meshPhytotherapyen_US
dc.subject.meshPlant Extracts - Therapeutic Useen_US
dc.subject.meshSanguisorbaen_US
dc.titleEffect of Sanguisorba officinalis L on breast cancer growth and angiogenesisen_US
dc.typeArticleen_US
dc.identifier.emailChen, JP: abchen@hku.hken_US
dc.identifier.authorityChen, JP=rp01316en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1517/14728222.2011.642371en_US
dc.identifier.pmid22316502-
dc.identifier.scopuseid_2-s2.0-84863260112en_US
dc.identifier.hkuros189764-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863260112&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issueSUPPL. 1en_US
dc.identifier.spageS79en_US
dc.identifier.epageS89en_US
dc.identifier.isiWOS:000300712100012-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridWang, Z=7410054221en_US
dc.identifier.scopusauthoridLoo, WT=7003567474en_US
dc.identifier.scopusauthoridWang, N=55251266100en_US
dc.identifier.scopusauthoridChow, LW=34975216600en_US
dc.identifier.scopusauthoridWang, D=36955783900en_US
dc.identifier.scopusauthoridHan, F=23569225000en_US
dc.identifier.scopusauthoridZheng, X=55276698400en_US
dc.identifier.scopusauthoridChen, JP=22733695400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats